A Real-World Study Evaluating Drug Tolerability and Health Care Resource Use with Acalabrutinib Versus Ibrutinib in First-Line Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Daniel Ermann[1], George Dranitsaris[2,3], Sibel Blau[2], Aaron Peevyhouse[2], Heather Neuhalfen[2], Vikram Shetty[4], Dipen Patel[4], Samantha L Thompson[5], Anna Teschemaker[4], and Mayur Narkhede[6]

[1]University of Utah, Salt Lake City, UT, USA, [2]ONCare Alliance, Tacoma, WA, USA, [3]Syracuse University, Syracuse, NY, USA, [4]AstraZeneca, Gaithersburg, MD, USA, [5]AstraZeneca, Cambridge, UK, [6]The University of Alabama at Birmingham, Birmingham, AL, USA

EE457

Supplementary Materials

Supplementary Table 1. Demographic and clinical characteristics of patients at the start of BTKi monotherapy

Parameter[a]	Acalabrutinib n = 227	Ibrutinib n = 227
Median age, years (IQR)	72 (46–90)	73 (50–88)
Female sex, n (%)	80 (35.2)	95 (41.8)
Race, n (%)		
White	202 (89.0)	197 (86.8)
Black	13 (5.7)	14 (6.2)
Other	6 (2.6)	11 (4.8)
Not documented	6 (2.6)	5 (2.2)
ECOG PS, n (%)		
0	94 (41.4)	84 (37.0)
1	76 (33.5)	77 (33.9)
≥ 2	19 (8.4)	26 (11.4)
Not documented	38 (16.7)	40 (17.6)
SBP at start of therapy (IQR)	130 (101–173)	127 (97–170)
DBP at start of therapy (IQR)	72 (54–93)	71 (52–91)
Median Charlson comorbidity index (IQR)[b]	3 (2–8)	3 (2–8)
Clinical history 12 months before therapy, n (%)		
Atrial fibrillation	35 (15.4)	18 (7.9)
Cardiac arrhythmia	12 (5.3)	4 (1.8)
Cerebrovascular accident	7 (3.1)	4 (1.8)
Congestive heart failure	18 (7.9)	9 (4.0)
Hypertension	154 (67.8)	151 (66.5)
Left ventricular dysfunction	0 (0.0)	1 (0.4)
Valvular heart disease	13 (5.7)	8 (3.5)
Myocardial infarction	6 (2.6)	5 (2.2)
Ventricular arrhythmia	3 (1.3)	5 (2.2)
Transient ischemic attack	4 (1.8)	5 (2.2)
Clinically significant bleeding events	3 (1.3)	0 (0.0)
Venous thromboembolic event	4 (1.8)	1 (0.4)

[a]Percentages may not total 100 owing to rounding.
[b]Weighted comorbidity classes were: low = 0 points; median = 1–2; high = 3–4; and very high = ≥ 5.
BTKi, Bruton tyrosine kinase inhibitor; DBP, diastolic blood pressure; ECOG PS, Eastern Oncology Cooperative Group performance status; IQR, interquartile range; SBP, systolic blood pressure.

Supplementary Table 2. Supportive care drugs received during BTKi therapy

Parameter, n (%)	Acalabrutinib n = 227	Ibrutinib n = 227
ACE inhibitors	55 (24.2)	57 (25.1)
Calcium-channel blockers	59 (26.0)	60 (26.4)
α2-receptor agonists	2 (0.8)	7 (3.1)
β-blockers	67 (29.5)	74 (32.6)
Angiotensin II receptor blockers	43 (18.9)	39 (17.2)
Diuretics	56 (24.7)	65 (28.6)
α-blockers	2 (0.8)	7 (3.1)
Vasodilators	5 (2.2)	7 (3.1)
Clopidogrel	14 (6.2)	14 (6.2)
Apixaban	16 (7.0)	17 (7.5)
Rivaroxaban	6 (2.6)	2 (0.8)
Dabigatran	1 (0.4)	0 (0.0)
Warfarin	7 (3.1)	5 (2.2)

ACE, angiotensin-converting enzyme; BTKi, Bruton tyrosine kinase inhibitor.